Maxime Verhoeven

73 Validation of a prediction model for insufficient response to MTX REFERENCES 1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79 , 685-699 (2020). 2. Brown, P. M., Pratt, A. G. & Isaacs, J. D. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat. Rev. Rheumatol. 12 , 731–742 (2016). 3. Bakker, M. F. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 156 , 329–339 (2012). 4. Taylor, P. C. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatol. 58 , i17–i26 (2019). 5. Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389 , 2338–2348 (2017). 6. Wessels, J. A. M. et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56 , 1765–1775 (2007). 7. Teitsma, X. M. et al. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. Ann. Rheum. Dis. 77 , 1261–1267 (2018). 8. Sergeant, J. C. et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK rheumatoid arthritis medication study (RAMS). Arthritis Res. Ther. 20 , 147 (2018). 9. de Rotte, M. C. et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response tomethotrexate in rheumatoid arthritis. PLoS One 13 , e0208534 (2018). 10. Bijlsma, J.W.J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 , 343–355 (2016). 11. Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 13 , g7594 (2015). 12. Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 , 315–324 (1988). 13. Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62 , 2569–2581 (2010). 14. de Rotte, M. C. et al. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum. 65 , 2803–2813 (2013). 15. de Rotte, M. C. et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J. Rheumatol. 39 , 2032–2040 (2012). 16. van Steenbeek, C. D. et al. Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands. BMC Med. Res. Methodol. 19 , 117 (2019). 17. Burgers, L. E., Raza, K. & van der Helm-van Mil, A. H. Window of opportunity in rheumatoid arthritis-definitions and supporting evidence: from old to new perspectives. RMD Open 5 , e000870 (2019). 18. Smolen, J. S. et al. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann. Rheum. Dis. 77 , 1566–1572 (2018). 4